Navigation Links
ScienceBased Health Announces the Launch of Diavis(TM), a New Dietary Supplement for the 81 Million Americans With or at Risk for Diabetes
Date:11/10/2008

ATLANTA, Nov. 10 /PRNewswire/ -- The American Academy of Ophthalmology (AAO) 2008 Annual Meeting -- ScienceBased Health, a leading provider of premium nutraceuticals for eye health, today announced the launch of DiaVis, a specialized dietary supplement to support the visual and overall health of those with diabetes.

24 million Americans -- 8% of the population and nearly 25% of those 60 and older -- currently suffer from diabetes. When added to the 57 million Americans with pre-diabetes, an astounding 81 million Americans either have the condition or are considered at risk according to 2007 prevalence data from the CDC. Pre-diabetes, characterized by elevated blood sugar levels, is a precursor of adult-onset diabetes.

Diabetes is a disease in which the body does not produce or properly use insulin. As a result, blood glucose levels become too high. Those with diabetes are at an increased risk for developing a number of complications, such as heart disease, stroke and retinopathy. Retinopathy, estimated to affect up to 80% of those with diabetes over time, is the most common diabetic eye disease and a leading cause of blindness.

Research has identified nutrients that may be low in diabetics due to inadequate nutrient intake, increased excretion, and altered nutrient requirements due to higher oxidative stress or use of diabetes-related medications. Some studies have found diabetics and those with retinopathy to be low in antioxidants. Antioxidants have been found to play an important role in helping to combat oxidative stress, which plays a role in developing diabetic complications.

DiaVis delivers a blend of key antioxidants, including Pycnogenol(R), and other nutrients found to play a role in helping to combat oxidative stress and inflammation, and that tend to be marginally low in those with diabetes. Additionally, DiaVis delivers ingredients found to play a role in normal glucose metabolism and retinal vessel health.

"DiaVis was developed for those with diabetes as well as the overwhelming number of people with pre-diabetes, said Alain Magro, president, ScienceBased Health. "Research shows that damage to the body is already occurring in the pre-diabetes phase and that certain nutrients can play a crucial role in bolstering the body's defenses. We believe that DiaVis represents the most advanced scientific research on the role of nutrition in diabetic health."

DiaVis is now available through eyecare practitioners or ScienceBased Health: 888.433.4726; http;//www.sciencebasedhealth.com. DiaVis retails for $34.95 (30 day supply).

About ScienceBased Health

ScienceBased Health, a privately held company, develops and markets evidence-based nutraceuticals for eye health. The formulations, created by leading physicians, nutrition scientists and researchers, are based on the latest scientific research and are recommended by several thousand ophthalmologists and optometrists nationwide. The Company developed HydroEye(R), a patented, oral formulation for dry eyes; OcularProtect(R), a comprehensive multinutrient for eyes and overall body health; MacularProtect Complete(R) and MacularProtect Complete(R)-S, powerful formulations, based on AREDS and other advanced research, to preserve macular and whole body health; Optic Nerve Formula(R), a powerful formulation to protect optic nerve health; DiaVis(TM), a targeted formulation for those with diabetes and at risk for diabetes; and other high quality products for eye and body health. The products are made from premium ingredients and manufactured according to highest quality standards. For more information, contact ScienceBased Health at: (888) 433-4726 or visit: http://www.sciencebasedhealth.com.


'/>"/>
SOURCE ScienceBased Health
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Health Robotics Announces Strategic Partnership in Japan for its CytoCare(TM) Robot with TOSHO Inc.
2. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
3. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
4. ViroPharma to Present at Three November Healthcare Conferences
5. Transgenomic to Present at Rodman & Renshaw 10th Annual Healthcare Conference
6. Onyx Pharmaceuticals to Present at the 2008 Credit Suisse Health Care Conference
7. Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
8. APS Healthcare Moves Headquarters to White Plains, NY
9. BioMarin to Present at the Credit Suisse Healthcare Conference
10. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
11. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... line of medical marijuana products targeting the needs of consumers who are incorporating ... Kindred takes place in Phoenix, Arizona. , As operators of two successful Valley ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the ... and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their ...
(Date:10/6/2017)... ... October 06, 2017 , ... On ... and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The ... The event is free and open to the public, but registration is required. ...
Breaking Biology Technology:
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):